The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an ...
PrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Starting Tuesday, misoprostol and mifepristone will be categorized in Louisiana as Schedule IV medications, that is, categorized as drugs with a potential for abuse and risk of dependence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback